CAR T-Cell Therapy Market Size, Share, Growth, Forecast 2030

CAR T-Cell Therapy Industry Perspective:    

The global CAR T-cell therapy market size was evaluated at $378.49 million in 2022 and is predicted to hit $2,406.39 million by the end of 2030 with a CAGR of nearly 26.20% between 2023 and 2030.

Request Free Sample

CAR T-Cell Therapy Market: Overview

CAR T-cell therapy is a kind of cancer immunotherapy that makes use of genetically modified immune cells referred to as T-cells for locating cancer tissues and destroying them. In addition to this, there are three steps involved in the CAR T-cell therapy that include collection of T-cells, infusing of CAR-T cells in the human body, and T-cell engineering. For the record, CAR T-cell therapy is an FDA-approved treatment that can be utilized for treating hematological malignancies such as multiple myeloma, leukemia, and lymphoma.

Key Insights

• As per the analysis shared by our research analyst, the global CAR T-cell therapy market is projected to expand annually at the annual growth rate of around 26.20% over the forecast timespan (2023-2030)
• In terms of revenue, the global CAR T-cell therapy market size was evaluated at nearly $378.49 million in 2022 and is expected to reach $2,406.39 million by 2030.
• The global CAR T-cell therapy market is anticipated to record massive growth over the forecast period owing to a rise in the occurrence of cancer and demand for apt modes of treating the disease.
• In terms of drug type, the axicabtagene ciloleucel segment is slated to register the fastest CAGR over the analysis period.
• Based on the indication, the lymphoma segment is predicted to lead the segmental surge over the forecast timeframe.
• On the basis of end-user, the hospital segment is predicted to dominate the segmental expansion over the forecast timespan.
• Region-wise, the Asia-Pacific CAR T-cell therapy market is projected to register the highest CAGR during the assessment timeline.

CAR T-Cell Therapy Market: Growth Factors

An increase in the incidences of cancer will trigger the global market growth trends over 2023-2030

The rise in the occurrence of cancer and demand for apt modes of treating the disease is set to impel the expansion of the global CAR T-cell therapy market. Additionally, favorable compensation policies and an increase in awareness about this treatment mode will prompt global market trends. Moreover, less time is required by CAR T-cell therapy for treating the cancer disease and this will catapult the global market trends. Reportedly, clinical tests in blood cancers have demonstrated that patients in whom cancer recurred after various modes of treatments, when treated with CAR T-cell therapy achieved remissions which lasted for many years. Furthermore, subjects treated with CAR T-cell therapy also benefitted from curative cancer therapy such as stem cell transplants. All these aforementioned aspects are likely to steer the growth of the global market in the years to come. Moreover, six CAR T-cell therapies have been approved by the U.S. FDA since 2017. All these therapies are approved for treating blood cancers such as a few types of leukemia, lymphomas, and multiple myeloma.

CAR T-Cell Therapy Market: Restraints

Side effects of CAR T-cell treatment can halt the growth of the global industry over the forecast period

Side effects of CAR T-cell therapy include headache, high fever, nausea, diarrhea, joint pain, vomiting, and loss of balance. In addition to this, other side effects of the therapy include allergic reactions, bleeding, fatigue, dizziness, low blood pressure, and difficulty in breathing. All these above-mentioned aspects can impede the growth of the CAR T-cell therapy industry across the globe.

CAR T-Cell Therapy Market: Opportunities

Strategic partnerships & new product launches can create new opportunities for growth in the global market

Launching new product will open new growth avenues for the global CAR T-cell therapy market. Furthermore, mergers & acquisitions, and partnerships will contribute lucratively towards the expansion of the global market in the upcoming years. For instance, in the first half of 2018, Gilead Sciences Inc., a biotech firm based in the U.S., joined hands with Sangamo Therapeutics Inc., a U.S.-based biotech company, for bringing improvements in gene editing techniques for treating cancer.

CAR T-Cell Therapy Market: Challenges

Demand for proficient manpower for executing CAR T-cell therapy can prove as a challenging factor in the growth of the global industry

The need for an efficient workforce for developing and implementing CAR T-cell treatments can prove to be a huge challenge for the expansion of the global CAR T-cell therapy industry. Other challenges faced by healthcare service providers include antigen escape, restricted tumor infiltration, and limited trafficking.

CAR T-Cell Therapy Market: Segmentation

The global CAR T-cell therapy market is sectored into drug type, indication, end-user, and region.

In drug type terms, the global CAR T-cell therapy market is segregated into axicabtagene ciloleucel, brexucabtagene autoleucel, tisagenlecleucel, and others segments. In addition to this, the axicabtagene ciloleucel segment, which garnered nearly 57% of the global market share in 2022, is projected to register the highest CAGR in the upcoming years. The growth of the segment in the upcoming years can be due to the massive use of Yescarta for treating large B-cell lymphoma as well as follicular lymphoma. Reportedly, Yescarta is a drug comprising active ingredients referred to as axicabtagene ciloleucel.

Based on indication, the global CAR T-Cell therapy industry is bifurcated into chronic lymphocytic leukemia, lymphoma, multiple myeloma, acute lymphocytic leukemia, and others segments. In addition to this, the lymphoma segment, which contributed majorly towards the global industry share in 2022, is set to establish a leading position in the global industry in the years to come. The segmental expansion over the assessment timeline can be due to a rise in the occurrence of non-Hodgkin lymphoma diseases across the globe. For the record, more than 5, 00,000 new cases of non-Hodgkin lymphoma diseases were reported across the globe in 2020.

On the basis of end-user, the global CAR T-cell therapy market is divided into hospitals and cancer treatment centers segments. Furthermore, the hospitals segment, which contributed majorly towards the global market revenue in 2022, is set to establish a segmental dominance over the forecast timeline. The segmental growth over the assessment timeframe can be owing to a rise in the application of CAR T-cell therapy for treating cancer patients admitted to hospitals.

CAR T-Cell Therapy Market: Report Scope

CAR T-Cell Therapy Market: Regional Insights

North America is likely to establish a leading position in the global market over 2023-2030

North America, which accounted for 27%of the global CAR T-cell therapy market share in 2022, will be the leading region during the predicted period. Moreover, the growth of the regional market over the anticipated timespan can be subject to the presence of life science firms in countries such as the U.S. Furthermore, a rise in the allocation of funds for research activities related launching of new kinds of cancer treatment mode will proliferate the regional market size. Some of the firms in the region are launching new methods of treating cancer. For instance, in April 2022, Kite Pharma, a U.S.-based biotech firm developing cancer immunotherapy products, introduced Yescarta CAR T-cell therapy for treating patients having large B-lymphoma. Such moves will drive regional market trends.

Request Free Sample

The Asia-Pacific CAR T-cell therapy industry is set to register the highest CAGR over the forecast timeframe owing to the presence of key players in countries such as India, China, South Korea, Thailand, Taiwan, and Japan. Apart from this, growing awareness about CAR T-cell therapy in the region and the availability of strong healthcare infrastructure facilities in the sub-continent will prop up the expansion of the industry in the region.

CAR T-Cell Therapy Market: Competitive Space

The global CAR T-cell therapy market profiles key players such as:

• Intellia Therapeutics
• Pfizer Inc.
• Autolus Therapeutics
• CARsgen Therapeutics Co. Ltd.
• Juno Therapeutics Inc.
• Sorrento Therapeutics Inc.
• bluebird bio Inc.
• CELGENE CORPORATION
• Eureka Therapeutics Inc.
• Avacta Life Sciences Ltd.
• Calyxt Inc.
• Celyad Oncology SA
• Fortress Biotech Inc.
• Amgen Inc.
• IMMUNE THERAPEUTICS INC
• Caribou Biosciences Inc.
• Gilead Sciences Inc.
• Merck KGaA
• Novartis AG
• Alaunos Therapeutics Inc.
• Poseida Therapeutics Inc.

The global CAR T-cell therapy market is segmented as follows:

By Drug Type

• Axicabtagene Ciloleucel
• Brexucabtagene Autoleucel
• Tisagenlecleucel
• Others

By Indication

• Chronic Lymphocytic Leukemia
• Lymphoma
• Multiple Myeloma
•  Acute Lymphocytic Leukemia
• Others

By End-User

• Hospitals
•  Cancer Treatment Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa